MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil

International Journal of Hematology

Volumn 75, Issue 2, 2002, Pages 178-181

  Fukushima, Toshihiro ^a   Yoshio, Nobuyuki ^a   Noto, Yutaka ^a   Kida, Hiroshi ^a  

^a National Kanazawa Hospital   (Japan)

Author keywords

Fluorouracil; MLL gene rearrangement; t(11; 17) (q23; q25); Tegafur uracil; Therapy related acute myelogenous leukemia

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MIXED LINEAGE LEUKEMIA PROTEIN; UFT; ANTINEOPLASTIC ANTIMETABOLITE; TEGAFUR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLON CANCER; DRUG MECHANISM; GENE REARRANGEMENT; HEMICOLECTOMY; HUMAN; MALE; REMISSION; CHEMICALLY INDUCED DISORDER; CHROMOSOME 11; CHROMOSOME 17; COLON TUMOR; DRUG ANTAGONISM; GENE TRANSLOCATION; GENETICS; SECOND CANCER;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE II; GENE REARRANGEMENT; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; NEOPLASMS, SECOND PRIMARY; TEGAFUR; TRANSLOCATION, GENETIC;

EID: 0036463676     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982024     Document Type: Article

References (25)

1. Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4:325-345.
2. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
3. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 1993;7:1975-1986.
4. Gill Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993;82:3705-3711.
5. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412-1417.
6. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992;3:107-111.
7. Nakajima T. Review of adjuvant chemotherapy for gastric cancer. World J Surg. 1995;19:570-574.
8. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996;14: 1048-1054.
9. Carver JH, Hatch FT, Branscomb EW. Estimating maximum limits to mutagenic potency from cytotoxic potency. Nature. 1979;279: 154-156.
10. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
11. Bower M, Parry P, Carter M, et al. Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/M5. Blood. 1994; 84:3776-3780.
12. Tien HF, Hsiao CH, Tang JL, et al. Characterization of acute myeloid leukemia with MLL rearrangements - no increase in the incidence of coexpression of lymphoid-associated antigens on leukemic blasts. Leukemia. 2000;14:1025-1030.
13. Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol. 2000;71:144-152.
14. Turker A, Guler N. Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report. Hematol Cell Ther. 1999; 41:195-196.
15. Shimano S, Murayama K, Katahira H, Tsuchiya J. A retrospective study of acute myelogenous leukemia and myelodysplastic syndrome cases - clinical and hematological findings [in Japanese]. Jpn J Cancer Clin. 1994;40:175-179.
16. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000;28:1457-1463.
17. Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol. 1983;54:58-119.
18. Maraschin J, Dutrillaux B, Aurias A. Chromosome aberrations induced by etoposide (VP-16) are not random. Int J Cancer. 1990; 46;808-812.
19. Broeker PLS, Super HG, Thirman MJ et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996;87:1912-1922.
20. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351-375.
21. Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J, Bradley MO. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res. 1985;45:3143-3149.
22. Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J. 2000;14:2339-2344.
23. Osaka M, Rowley JD, Zeleznik-Le NJ. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci U S A. 1999;96:6428-6433.
24. Taki T, Ohnishi H, Shinohara K, et al. AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25). Cancer Res. 1999;59:4261-4265.
25. Megonigal MD, Rappaport EF, Jones DH, et al. t(11;22) (q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc Natl Acad Sci U S A. 1998;95:6413-6418.